NCT05087589Unknown2 期
Efficacy, Safety and Immunological Evaluation of Tofacitinib in the Treatment of Primary Sjögren's Syndrome:a Prospective Observational Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Immunological Responses
研究概览
简要总结
This study aims to explore the clinical and immunological efficacy of tofacitinib on primary Sjögren's Syndrome
详细描述
The investigators designed a single center, open-label, prospective study. Adults with active primary Sjögren's Syndrome will be enrolled, meeting the American College of Rheumatology(ACR) & European allance of associations for rheumatology(EULAR)(2016) diagnostic criteria . Tofacitinib 5 mg bd was administered for 6 months to explore its efficacy and safety. The improvement of clinical and laboratory indexes was evaluated. Changes of immune cell subsets and cytokines were monitored.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female >18 years of age at screening visits
- •Patients meet the American-European Consensus Group 2002 classification criteria
- •The patient must be informed in writing of the consent to participate in the trial and the patient is expected to be able to comply with the requirements of the study follow-up plan and other protocols.
- •Dosing of antimalarials, prednisone or equivalent, cholinergic stimulants, and topical cyclosporine required to be stable for at least 4 weeks before screening and during study; maximum doses allowed:
- •Hydroxychloroquinone, 400 mg/day;
- •Prednisone, 10 mg/day
排除标准
- •Any subject meeting any of the following criteria should be excluded:
- •Laboratory abnormality:
- •Hb≤9 g/dl
- •Neutrophil <1.0 x 109/l
- •lymphocyte<0.5 x 109/l
- •Diagnosis of other autoimmune disease, or other sicca syndrome.
- •Use rituximab or other monoclonal antibodies within 6 months.
- •Received high doses of glucocorticoid (>10 mg/d) within 1 month.
- •Serious complications: including heart failure (≥ New York Heart Association (NYHA) class III), renal insufficiency (creatinine clearance ≤ 30 ml/min), liver dysfunction (serum Alanine transaminase (ALT) or aspartate aminotransferase (AST) greater than three times the upper limit of normal, or total bilirubin greater than Normal upper limit)
- •Known allergies, hyperreactivity or intolerance of tofacitinib or its excipients.
- •Have a serious infection needing hospitalization (including but not limited to hepatitis, pneumonia, bacteremia, pyelonephritis, EB virus, tuberculosis infection), or use intravenous antibiotics to treat infection in 2 months before the enrollment.
- •Infection with HIV (HIV antibody positive serology) or hepatitis C (Hep C antibody positive serology). If seropositive, it is recommended to consult a doctor who has expertise in treating HIV or hepatitis C virus infection.
- •Any known history of malignancy in the past 5 years (except for non-melanoma skin cancer, non-melanoma skin cancer or cervical tumor without recurrence within 3 months after surgical cure prior to the first study preparation).
- •Uncontrolled mental or emotional disorders, including a history of drug and alcohol abuse over the past 3 years, may hinder the successful completion of the study.
- •Pregnant, lactating women (WCBP) are reluctant to use medically approved contraceptives during treatment and 12 months after treatment.
研究组 & 干预措施
tofacitinib
Experimental
Tofacitinib 5mg was taken orally twice a day for 6 months
干预措施: Tofacitinib (Drug)
结局指标
主要结局
Immunological Responses
时间窗: week 24
Analysis interleukin 17 (IL-17)-producing helper T (Th17) cells before and during tofacitinib treatment. P values below 0.05 are considered statistically significant in this study.
次要结局
- Improvements in EULAR SS patient-reported index (ESSPRI), other clinical and immunological parameters(week 24)
- Safety and tolerability of tofacitinib as assessed by incidence of adverse events reported and observed(up tp 24 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Tofatib Treatment for IgG4-related DiseaseIgG4-related DiseaseNCT05625581Changhai Hospital40
已完成
3 期
Efficacy Study Of Tofacitinib In Pediatric JIA PopulationJuvenile Idiopathic ArthritisNCT02592434Pfizer225
招募中
3 期
Efficacy and safety of tofacitinib on clinical improvement in patients with COVID19COVID-19 pneumonia.Covid-19 diseaseU07.1IRCT20190804044429N7Mazandaran University of Medical Sciences240
尚未招募
不适用
Efficacy and Safety of Tofacitinib in Patients With Prurigo NodularisItchPrurigo NodularisNCT06201715Second Affiliated Hospital, School of Medicine, Zhejiang University24
已完成
1 期
Study of Tofacitinib in Refractory DermatomyositisDermatomyositisNCT03002649Johns Hopkins University10